cMyc Cancer Research Results

cMyc, cellular-MYC oncogene: Click to Expand ⟱
Source:
Type: oncogene
The MYC proto-oncogenes are among the most commonly activated proteins in human cancer. The oncogene c-myc, which is frequently over-expressed in cancer cells, is involved in the transactivation of most of the glycolytic enzymes including lactate dehydrogenase A (LDHA) and the glucose transporter GLUT1 [51,52]. Thus, c-myc activation is a likely candidate to promote the enhanced glucose uptake and lactate release in the proliferating cancer cell. The c-Myc oncogene is a ‘master regulator’ of both cellular growth and metabolism in transformed cells.
-C-myc is a common oncogene that enhances aerobic glycolysis in the cancer cells by transcriptionally activating GLUT1, HK2, PKM2 and LDH-A

Inhibitors (downregulate):
Curcumin
Resveratrol: downregulate c-Myc expression.
Epigallocatechin Gallate (EGCG)
Quercetin
Berberine: decrease c-Myc expression and repress its transcriptional activity.
Scientific Papers found: Click to Expand⟱
4388- AgNPs,    Differential Cytotoxic Potential of Silver Nanoparticles in Human Ovarian Cancer Cells and Ovarian Cancer Stem Cells
- in-vitro, Cerv, NA
tumCV↓, CSCs↓, selectivity↑, Apoptosis↑, ROS↑, LDH↓, Casp3↑, BAX↑, Bak↑, cMyc↑, MMP↓,
5553- BBM,    A review on berbamine–a potential anticancer drug
- Review, Var, NA
P-gp/ABCB1↓, MDR1↓, survivin↓, NF-kB↓, TumCP↓, TumCCA↑, Apoptosis↑, SMAD3↑, P21↑, cycD1/CCND1↓, cMyc↑, Bcl-2↓, Bcl-xL↓, BAX↑, CaMKII ↓, ChemoSen↑, MMP2↓, MMP9↓, TIMP1↑, cl‑Casp3↑, cl‑Casp9↑, cl‑Casp8↑, cl‑PARP↑, IL6↓, ROS↑,
975- Est,    Estrogen inhibits autophagy and promotes growth of endometrial cancer by promoting glutamine metabolism
- vitro+vivo, UEC, NA
GLS↑, cMyc↑, GlutMet↑, tumCV↑, TumAuto↓,
2914- LT,    Therapeutic Potential of Luteolin on Cancer
- Review, Var, NA
*antiOx↑, *IronCh↑, *toxicity↓, *BioAv↓, *BioAv↑, DNAdam↑, TumCP↓, DR5↑, P53↑, JNK↑, BAX↑, cl‑Casp3↑, cl‑Casp8↑, cl‑Casp9↑, cl‑PARP↑, survivin↓, cycD1/CCND1↓, CycB/CCNB1↓, CDC2↓, P21↑, angioG↓, MMP2↓, AEG1↓, VEGF↓, VEGFR2/KDR/Flk1↓, MMP9↓, CXCR4↓, PI3K↓, Akt↓, ERK↓, TumAuto↑, LC3B-II↑, EMT↓, E-cadherin↑, N-cadherin↓, Wnt↓, ROS↑, NICD↓, p‑GSK‐3β↓, iNOS↓, COX2/PTGS2↓, NRF2↑, Ca+2↑, ChemoSen↑, ChemoSen↓, IFN-γ↓, RadioS↑, MDM2↓, NOTCH1↓, AR↓, TIMP1↑, TIMP2↑, ER Stress↑, CDK2↓, Telomerase↓, p‑NF-kB↑, p‑cMyc↑, hTERT/TERT↓, RAS↓, YAP/TEAD↓, TAZ↓, NF-kB↓, NRF2↓, HO-1↓, MDR1↓,
4833- Uro,    Unveiling the potential of Urolithin A in Cancer Therapy: Mechanistic Insights to Future Perspectives of Nanomedicine
- Review, Var, NA - Review, AD, NA - Review, IBD, NA
BioAv↝, TumAuto↝, TumCG↓, TumMeta↓, ChemoSen↑, Imm↑, RadioS↑, BioAv↑, other↝, eff↓, *antiOx↓, *Inflam↓, AntiCan↓, AntiAge↑, chemoP↑, *neuroP↑, *ROS↓, *cognitive↑, *lipid-P↓, *cardioP↑, *TNF-α↓, *IL6↓, GutMicro↑, TumCCA↑, Apoptosis↑, angioG↓, NF-kB↓, PI3K↓, Akt↓, Casp↑, survivin↓, TumCP↓, cycD1/CCND1↓, cMyc↑, BAX↑, Bcl-2↓, COX2/PTGS2↓, P53↑, p38↑, *ROS↓, *SOD↑, *GPx↑, SIRT1↑, FOXO1↑, eff↑, ChemoSen↑,

Showing Research Papers: 1 to 5 of 5

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 5

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

HO-1↓, 1,   NRF2↓, 1,   NRF2↑, 1,   ROS↑, 3,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

CDC2↓, 1,   MMP↓, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

cMyc↑, 4,   p‑cMyc↑, 1,   GLS↑, 1,   GlutMet↑, 1,   LDH↓, 1,   SIRT1↑, 1,  

Cell Death(tgid=5) ⓘ

Akt↓, 2,   Apoptosis↑, 3,   Bak↑, 1,   BAX↑, 4,   Bcl-2↓, 2,   Bcl-xL↓, 1,   Casp↑, 1,   Casp3↑, 1,   cl‑Casp3↑, 2,   cl‑Casp8↑, 2,   cl‑Casp9↑, 2,   DR5↑, 1,   hTERT/TERT↓, 1,   iNOS↓, 1,   JNK↑, 1,   MDM2↓, 1,   NICD↓, 1,   p38↑, 1,   survivin↓, 3,   Telomerase↓, 1,   YAP/TEAD↓, 1,  

Kinase & Signal Transduction(tgid=6) ⓘ

CaMKII ↓, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

other↝, 1,   tumCV↓, 1,   tumCV↑, 1,  

Protein Folding & ER Stress(tgid=8) ⓘ

ER Stress↑, 1,  

Autophagy & Lysosomes(tgid=9) ⓘ

LC3B-II↑, 1,   TumAuto↓, 1,   TumAuto↑, 1,   TumAuto↝, 1,  

DNA Damage & Repair(tgid=10) ⓘ

DNAdam↑, 1,   P53↑, 2,   cl‑PARP↑, 2,  

Cell Cycle & Senescence(tgid=11) ⓘ

CDK2↓, 1,   CycB/CCNB1↓, 1,   cycD1/CCND1↓, 3,   P21↑, 2,   TumCCA↑, 2,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

CSCs↓, 1,   EMT↓, 1,   ERK↓, 1,   FOXO1↑, 1,   p‑GSK‐3β↓, 1,   NOTCH1↓, 1,   PI3K↓, 2,   RAS↓, 1,   TAZ↓, 1,   TumCG↓, 1,   Wnt↓, 1,  

Migration(tgid=13) ⓘ

AEG1↓, 1,   Ca+2↑, 1,   E-cadherin↑, 1,   MMP2↓, 2,   MMP9↓, 2,   N-cadherin↓, 1,   SMAD3↑, 1,   TIMP1↑, 2,   TIMP2↑, 1,   TumCP↓, 3,   TumMeta↓, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↓, 2,   VEGF↓, 1,   VEGFR2/KDR/Flk1↓, 1,  

Barriers & Transport(tgid=15) ⓘ

P-gp/ABCB1↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

COX2/PTGS2↓, 2,   CXCR4↓, 1,   IFN-γ↓, 1,   IL6↓, 1,   Imm↑, 1,   NF-kB↓, 3,   p‑NF-kB↑, 1,  

Hormonal & Nuclear Receptors(tgid=20) ⓘ

AR↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↑, 1,   BioAv↝, 1,   ChemoSen↓, 1,   ChemoSen↑, 4,   eff↓, 1,   eff↑, 1,   MDR1↓, 2,   RadioS↑, 2,   selectivity↑, 1,  

Clinical Biomarkers(tgid=22) ⓘ

AR↓, 1,   GutMicro↑, 1,   hTERT/TERT↓, 1,   IL6↓, 1,   LDH↓, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiAge↑, 1,   AntiCan↓, 1,   chemoP↑, 1,  
Total Targets: 101

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↓, 1,   antiOx↑, 1,   GPx↑, 1,   lipid-P↓, 1,   ROS↓, 2,   SOD↑, 1,  

Metal & Cofactor Biology(tgid=2) ⓘ

IronCh↑, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

IL6↓, 1,   Inflam↓, 1,   TNF-α↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 1,   BioAv↑, 1,  

Clinical Biomarkers(tgid=22) ⓘ

IL6↓, 1,  

Functional Outcomes(tgid=23) ⓘ

cardioP↑, 1,   cognitive↑, 1,   neuroP↑, 1,   toxicity↓, 1,  
Total Targets: 17

Scientific Paper Hit Count for: cMyc, cellular-MYC oncogene
1 Silver-NanoParticles
1 Berbamine
1 Estrogen
1 Luteolin
1 Urolithin
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:0  prod#:%  Target#:35  State#:%  Dir#:2
  wNotes=0  sortOrder:rid,rpid

 

Home Page